Fundz

Avalyn Pharma Inc. reported raising $35.5 Million in an initial SEC Form D filing, from an offering of $35.7 Million

PUBLIC · AVLNMay 08, 2020

Amount Raised

$35.5 Million

$35.5 Million sold, per SEC Form D (first sale May 8, 2020)

Round Type

Venture

CambridgeBiotechnologyHealthcareHealth Care

Who to call at Avalyn, and when

A new round usually means Avalyn is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Avalyn raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Avalyn, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Avalyn

Location

245 First Street, 18th Floor

Cambridge, Massachusetts, United States

About

Avalyn is reimagining the future of pulmonary fibrosis treatment, with a pipeline of new inhaled formulations of approved medicines. Unlike currently available oral therapies, our inhaled approach allows us to tackle the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs – improving tolerability by decreasing systemic exposure and improving efficacy by increasing lung exposure. Our lead candidate, AP01, is an optimized inhaled formulation of pirfenidone, currently being studied for progressive pulmonary fibrosis in the Phase 2b MIST study. In addition, we completed two Phase 1 studies for AP02, an optimized inhaled formulation of nintedanib. At Avalyn, we are driven by our mission to empower lives through breakthrough inhaled therapies for interstitial lung diseases, turning breathlessness into hope.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Avalyn raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

3 contacts
Verified contacts24 people are listed at Avalyn. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Avalyn's next move

See what Strategic adds

Avalyn raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.